Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease


AltruBio Inc

We are encouraged by the quick engagement of more than 15 clinical sites across the US and rapid patient enrollment. This enthusiasm really demonstrates the continued unmet need in SR-aGVHD and desire from Key Opinion Leaders for better treatment options by leveraging the unique mechanism of action.

AltruBio Inc. http://www.altrubio.com, a clinical stage biotech company pioneering the PSGL-1 agonist approach in Immunology, announced today the first patient has been dosed in its phase 1b trial of Neihulizumab in patients with Steroid Refractory Acute Graft Versus Host Disease (SR-aGVHD). The trial is a multi-dose study of Neihulizumab in SR-aGVHD and follows its successful Phase 1a single-dose study which demonstrated a 77% response rate.

President & CEO Dr. Judy Chou stated “We are encouraged by the quick engagement of more than 15 clinical sites across the US and rapid patient enrollment. This enthusiasm really demonstrates the continued unmet need in SR-aGVHD and desire from Key Opinion Leaders for better treatment options by leveraging the unique mechanism of action of Neihulizumab.”

The study is intended to demonstrate the safety, tolerability, and efficacy of multiple doses of Neihulizumab in SR-aGVHD. Primary endpoints include the pharmacokinetic (PK) profile and complete response rate at day 28. A number of secondary endpoints for efficacy are specified including overall response rate at day 28, duration of response, and non-relapse mortality rate at day 180.

About Neihulizumab.

Neihulizumab is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes chronically activated T cells. This mechanism has been evaluated in four autoimmune and inflammatory diseases and has demonstrated clinical proof of concept and safety in more than 160 patients. Neihulizumab has completed Phase 2 trials in Psoriasis and Psoriatic Arthritis, is closing out in a Phase 2a trial for the treatment of refractory ulcerative colitis, and is in Phase 1 trials for the treatment of SR-aGVHD, with encouraging results in patients that are refractory to available therapies. A Phase 1 trial for the treatment of front-line acute GvHD is also currently initiated.

About acute Graft-versus-Host Disease.

Acute GvHD is a major complication following an allogeneic HCT. Somewhere between 30 and 70 percent of transplant recipients develop acute GvHD. Standard first –line treatment is systemic, high-dose glucocorticoid, with around 50% response rate and are associated with clinically significant side effects. Patients who do not respond to corticosteroid treatment are considered steroid-refractory. SR-aGVHD is a significant unmet medical need and novel, effective treatments are urgently needed.

The information presented here is not intended nor implied to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the advice of your physician or other qualified healthcare professional with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it.

About AltruBio Inc. (http://www.altrubio.com)

AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’s pipeline includes two clinical stage product candidates: (i) Neihulizumab (AbGn-168H) an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. AbGn-107 has demonstrated encouraging results in chemo-refractory gastric, pancreatic, colorectal and biliary cancers.

Note on Forward-Looking Statements

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

Share article on social media or email:

Better Noise Films “SNO BABIES”


Sno Babies film poster

Out NOW via Prime Video, iTunes, FandangoNow, Google Play and Vudu. http://snobabies.ffm.to/watch

Better Noise Films’ gripping and emotive tale SNO BABIES premieres on On-Demand & Digital platforms worldwide on Tuesday, September 29. Bridget Smith’s directorial debut, SNO BABIES is one of the year’s most important, provocative films starring Katie Kelly (Game of Silence), Paola Andino (Queen of the South), Michael Lombardi (Rescue Me), Shannan Wilson (Elementary) and is produced by Allen Kovac, Mike Walsh and Michael Lombardi.

“Katie Kelly delivers a powerful and heartbreaking performance” – Mara Reinstein, US WEEKLY

SNO BABIES depicts the grim realities of addiction and its effects on a middle-class suburban town. Kristen and Hannah are teenage best friends–smart, likable and college-bound– and addicted to heroin. The pair of seemingly unlikely addicts spiral down a path of destruction, hiding their secret from well-meaning but busy parents behind pink bedrooms and school uniforms. SNO BABIES shows how easy it can be to both miss and hide the signs of addiction behind the façade of “good” neighborhoods and pleasant, busy communities.

WATCH WITH…

Prime Video, FandangoNow, iTunes, MovieSpree, Google Play and Vudu

https://snobabies.ffm.to/watch

More than just a movie, SNO BABIES is a reminder that we can change perceptions and through the power of our networks and communities, we can save lives. Sno Babies raises money for the Global Recovery Initiatives Foundation (GRI) and the Amy Winehouse Foundation, to help fund critical support services for people in recovery. Better Noise Films’ share of profits from the film and all artist royalties from the soundtrack are being donated to these two worthy organizations with matching contributions from Better Noise Music.

“We know from personal experience the devastation and heartbreak that addiction can bring. Since setting up the Amy Winehouse Foundation in our daughter’s memory 9 years ago, we have learnt so much about this condition. We have also learnt that recovery is possible and people can go on to live wonderful and fulfilling lives,” says Mitch Winehouse of the Amy Winehouse Foundation. “We’ve made it our mission to work with people in recovery and to support young people who are struggling with the same sorts of issues as Amy and we’re delighted that Better Noise and SNO BABIES are helping us to do that.”

“Katie Kelly has an amazing performance that is tough, but an important one to watch. It’s definitely a film that makes you just sit and think for a while after. Truly heart-wrenching.” – Bailey Briggs, THE REEL DALLAS

SNO BABIES is the first feature from Better Noise Films, a new venture from Allen Kovac. In addition to his recording company Better Noise Music, Kovac has managed artists such as Bee Gee’s, Luther Vandross, Blondie, Meatloaf, Mötley Crüe and The Cranberries. Most recently Kovac has co-produced Netflix 2018 sensation ‘The Dirt’ based on the life of Mötley Crüe, with a 95% audience rating on Rotten Tomatoes. Kovac has also produced many TV Documentaries such as HBO special ‘The Bee Gee’s One Night Only’, MTV VH1 special ‘Mötley Crüe’s Resurrection of Mötley Crüe’, and ‘Meat Loaf: In Search of Paradise.’ SNO BABIES is the first of two 2020-21 releases for Kovac’s Better Noise Films.

Kovac said, “Studio heads, agents and managers know there is nothing sadder than when an artist or actor you’ve worked with passes away through misadventure. This movie is a wakeup call to the entertainment industry that we can’t lose more brilliant artists like Prince, Tom Petty, Juice Wrld, Mac Miller, Lil Peep, Philip Seymour Hoffman, or River Phoenix.” He continued “With over 70,000 people dying of drug overdoses in 2019 in the USA, this film is a way parents can open up the conversation of drugs with their kids before they go to college, an older brother can share a link to SNO BABIES to his younger brother to watch and say that he’s there to answer any questions afterwards, or for a rehab group to watch together. This is a conversation we need to have in the USA to destigmatize addiction. I have worked with Nikki Sixx of Mötley Crüe and SIXX:AM for 13 years to make this a global conversation to save lives, please join us!“

With the country’s opioid epidemic spiking from as a fesult of the COVID virus, the entertainment industry continues to lose its best and brightest to substance use disorders. Better Noise Entertainment has committed to fighting this problem and has collaborating with the Global Recovery Initiatives Foundation (GRI) to raise funds that will support of recovery and directly benefit struggling communities. Better Noise Entertainment will use their expertise in content creation, audience connection and creative storytelling to develop and amplify messaging to a wide pop-culture audience. Other entertainment industry companies partnering on this project to save lives include Live Nation, Ticketmaster, iHeart, Pandora, Sirius, Entercom and Cumulus among others.

“Powerful! A Must- See Movie For All Families Who Have a Loved One Struggling With Addiction”

– THE SOBER WORLD

The official SNO BABIES soundtrack, which is now available for streaming and download, features some of today’s biggest rock artists including Cory Marks, Bad Wolves, Hellyeah and Sixx: A.M. as well as the ‘supergroup’ collaboration from SIXX:A.M. Presents: Artists For Recovery – “Maybe It’s Time” (feat. Corey Taylor, Joe Elliott, Brantley Gilbert, Ivan Moody, Slash, AWOLNATION, Tommy Vext.

For additional information on the film, please visit https://snobabiesmovie.com/

Assets can be found at https://bit.ly/SnoBabiesAssets

#LETSSAVELIVES

ABOUT BETTER NOISE FILMS

Better Noise Films (BNF), a Better Noise Entertainment company (BNE), is led by entertainment industry pioneer, Allen Kovac (CEO) and COO Dan Lieblein (Cinecom, October Films, and USA Films). BNF develops feature films, unique programming and other original content. Along with Better Noise Music, a leading global independent record label, Better Noise Films serves as an emerging platform for delivering top quality content that engages audiences, develops artists and builds the BNE brand. The company’s first 2 releases are SNO BABIES (due out Fall 2020) and THE RETALIATORS (comes out March 2021).

ABOUT BETTER NOISE MUSIC:

BETTER NOISE MUSIC is the premier independent music label under BETTER NOISE ENTERTAINMENT, a content creation and marketing company that produces music, books, films, documentaries, TV shows, theatrical productions and tours. Better Noise Music (formerly Eleven Seven Music), founded in 2006 by music industry veteran and independent pioneer Allen Kovac, focuses on artist development and has grown into a music industry independent powerhouse, with a roster including Five Finger Death Punch, AWOLNATION, Mötley Crüe, Atlas Genius, Papa Roach, Bad Wolves, Nothing More and The Hu. Partnering with FUGA, AMPED and Membran, the company operates a global marketing and distribution platform with offices in New York, Los Angeles, Nashville, London, Berlin, Toronto and Sydney. https://betternoise.com/

ABOUT THE GLOBAL RECOVERY INITIATIVES

The Global Recovery Initiatives Foundation (GRI) is the first and only national community foundation dedicated to building a philanthropic source of funding for organizations to expand their capacity to provide people with substance abuse disorder recovery support services.

GRI supports organizations using evidence-based programs that have demonstrated success in:

  • Engagement of philanthropy leaders to invest in recovery focused non profit initiatives
  • Reducing the stigma around substance use disorders, and recovery.
  • Deploy public, private and pop culture resources to strengthen the field of recovery.

For more information visit: https://globalrecoveryinitiatives.org/

ABOUT THE AMY WINEHOUSE FOUNDATION

Following Amy’s untimely death in 2011, the Winehouse family set up the Amy Winehouse Foundation to support, inform and inspire vulnerable and disadvantaged young people. Today, through their range of projects, they work with thousands of young people both in the UK and abroad. The charity has three core areas of focus:

  • To inform and educate young people about the effects of drug & alcohol misuse.
  • To provide support for those most vulnerable, those at high risk of misuse or disadvantaged through circumstance.
  • To support the personal development of disadvantaged children and young people through music


Registered charity no. 1143740 (England and Wales) http://www.amywinehousefoundation.org

  • Amy Winehouse Foundation (a charity registered in England and Wales with registration number 1143740) will receive all profits obtained in the UK by 11-7 Recording Corp. (doing business as Better Noise Music), estimated to be approximately £40,000 in total.

For US release information, please contact:

Lee Meltzer / R&CPMK / Lee.Meltzer@rogersandcowanpmk.com

Jamie Roberts / Better Noise Entertainment / jamie@betternoise.com

COVID19-Era Trends Accelerates Distribution Growth of Gutzy Organic®


…trend towards foods with functional benefits…

Keep Moving, Inc., maker of the gutzy organic brand of gut-healthy snacks, is experiencing accelerated distribution growth as a result of COVID-era consumer trends. Gutzy® plant-based organic fruit, veg and botanical pouches are now available on refrigerated shelves at Meijer and Ingles stores, as well as online at Amazon.com.

Since March, there has been a surge in activity that reflects consumers proactively managing their own health. From the way they shop (~40% increase in online grocery shopping) to what they buy (eating healthier foods with greater functional benefits), the shifts have kept both retailers and food companies on their toes to meet consumers evolving demands. A big focus for retailers is on category management and product mix, assessing and optimizing to ensure the healthier, immune-boosting products that consumers are seeking are available.

David Istier, Founder and CEO of Gutzy Organic, said “this trend has helped gutzy expand our distribution by about 650 stores in just a few short months. It also pushed us to offer gutzy direct to consumers (DTC) now – we’ve just launched several flavor varieties on Amazon. Consumers are more aware of the role the gut plays in overall health, particularly immune system functioning and emotional and mental resilience. There’s been a surge in online searches for things like ‘foods that support gut health’ and ‘prebiotics and probiotics.’ Each pouch of gutzy has 5-6g of prebiotics – both consumers and retail buyers love it.”

Feedback from gutzy fans led the company to offer several DTC flavor options in 32-pouch packs. Input from gutzy consumers proved invaluable; Amazon sales have exceeded expectations. Istier said “new and old fans love it – they get a month’s supply of gutzy delivered right to their door.” Gutzy also offers a 16-pouch trial pack for those new to the brand.

Istier added “the launch of gutzy’s Raspberry, Blueberry & Beet gut-healthy snack earlier this year has had notable success in gaining distribution. The new item beautifully blends the antioxidant-rich superfoods raspberries, blueberries and beets, critical B and C vitamins and prebiotics to create an amazingly delicious and gut-healthy snack.”

Gutzy expects to roll out in more than 350 additional stores by the end of the year and will then be available in 4,000 stores nationwide.

About Gutzy

Keep Moving, Inc. was founded by French entrepreneur David Istier to provide on-the-go adults with the world’s first organic gut-healthy fruit, veggie superfood snack under the Gutzy Organic® brand. Gutzy creates snacks for people who understand the importance of balanced eating and gut health. Gutzy is available in the produce and/or grab-and-go refrigerated snack sections of retailers across the US, including Publix, Hannaford, Safeway, Wegmans, Meijer, CVS, The Fresh Market, Ingles and select Walmart stores.

Share article on social media or email:

Deirdre J. Cohen, MD, MS, Appointed as Director of Gastrointestinal Oncology Program of Mount Sinai Health System


Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.

Dr. Cohen will also be an Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. In these roles, she will conduct important translational and clinical research, including studies that build upon scientific discoveries developed at Mount Sinai and collaborating institutions.

As Director of the GI Oncology Program, Dr. Cohen will foster both clinical and research activities associated with GI cancers across the Mount Sinai cancer sites. She will also oversee the development of clinical trials in her role as Medical Director of the Cancer Clinical Trials Office. Dr. Cohen has abundant experience as Principal Investigator on numerous trials for novel therapeutic approaches for gastrointestinal cancer in particular.

“We are very proud that Dr. Cohen has decided to join us to help lead our efforts in gastrointestinal cancers,” said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at Mount Sinai, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai. “We are excited to welcome her to also further develop our already robust clinical trial office.”

Prior to joining Mount Sinai, Dr. Cohen was on the faculty in the Division of Medical Oncology at New York University (NYU) for 13 years. Recently, she served as Medical Director for the Perlmutter Cancer Center Clinical Trials Office and Acting Director of NYU GI Medical Oncology. Board certified in internal medicine, medical oncology, and hematology, Dr. Cohen is a member of the American Society of Clinical Oncology and the National Cancer Institute Colon Task Force.

Dr. Cohen received her MD from SUNY Health Science Center at Brooklyn and a Master of Science in Clinical Investigation from New York University. She completed a residency in internal medicine at NewYork-Presbyterian/Weill Cornell Medical Center and a fellowship in hematology/oncology at NYU Langone School of Medicine.

“Dr. Cohen’s arrival is an exciting step forward for coordinating a multidisciplinary approach for gastrointestinal cancer that builds on a strong foundation already here,” said William K. Oh, MD, Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute at Mount Sinai and the Ezra M. Greenspan, M.D. Professor in Clinical Cancer Care Therapeutics. “We are driven to continue to develop more effective therapies in trials for a constellation of cancers that take so many lives every year.”

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Mediaplanet and Camila Coelho Team Up for Neurological Disorders Awareness


News Image

Up to one billion people, nearly one-sixth of the world’s population, suffer from neurological disorders, with some 6.8 million dying of the disorders each year.

Mediaplanet is proud to announce the launch of its fall edition “Neurological Disorders” campaign, out today within USA TODAY and online. As the COVID-19 pandemic continues to strain our healthcare system, there is an incredible need for heightened awareness surrounding brain diseases affecting millions across the country.

Up to one billion people, nearly one-sixth of the world’s population, suffer from neurological disorders, with some 6.8 million dying of the disorders each year. There is no cure for any of these disorders, and patients, healthcare professionals, and family caregivers alike are in desperate need of improved therapies and technologies that will help manage their symptoms and improve their quality of life.

Among several conditions, epilepsy in children and adults is a major focal point of the campaign. Cover story Camila Coelho experienced her first seizure at nine years old, and just recently opened up about her condition to her massive social media fanbase. The successful designer and fashion & beauty influencer speaks openly about how difficult it was to accept her condition, and how the moment she decided to tell the world after sharing so much already affected and inspired her to do more. “I started thinking, I have this huge platform, I have this amazing community, and this is the only thing I have never shared before…I got to hear so many people’s stories, stories that really inspired me a lot and really helped me make decisions in my own life I’m living now, especially with pregnancy,” she said.

As the Epilepsy Foundation’s newest ambassador and board member, Coelho looks forward to helping others find the confidence to speak out about their condition. “Working with the Epilepsy Foundation, my biggest goal is to use my story to educate our society and community about epilepsy,” she said. “A lot of people don’t know what to do if you have a seizure next to them, or they wouldn’t even know what it is. I’m trying to educate my community on what epilepsy is and how to end stigma.”

The print component of “Neurological Disorders” is distributed within today’s edition of USA TODAY in Atlanta, Boston, the Carolinas, Chicago, Dallas, Detroit, Houston, Los Angeles, Minneapolis, New Orleans, New York, North/Central Florida, Philadelphia/Baltimore, Pittsburgh/Cleveland, San Francisco, South Florida and Washington, D.C. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit https://www.futureofpersonalhealth.com/campaign/neurological-disorders/.

This campaign was made possible by UCB, American Brain Foundation, Nicklaus Children’s Hospital, NeuroDerm American Neurological Association, NORD, American Stroke Association, Valley Children’s Healthcare, Epilepsy Foundation, Child Neurology Foundation, Dravet Syndrome Foundation, CACNA1A Foundation, Alzheimer’s Association, American Parkinson Disease Association,

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do

Press Contact:

Victoria Borkowski

(646) 755-7949

victoria.borkowski@mediaplanet.com

Share article on social media or email:

Hyland’s is Taking on Pain with New Natural Pain Relief Line Launch


Hyland’s Pain Relief*

Hyland’s pharmacists developed these new products as we believe they deserve natural pain relief that is tough on pain, yet gentle on the body. They have no known drug interactions or side effects, so you feel better, safely.” said Hyland’s President, Les Hamilton.

Pain affects more Americans than diabetes, heart disease, and cancer1, with one in four Americans declaring they suffered from pain lasting more than 24 hours.

Hyland’s is excited to launch a new line of pain relievers in 5 formulas that target common everyday pains for adults: migraine, headache, backache, general pain and a fever reducer. Made with natural active ingredients, these formulas are non-drowsy, non-habit forming and gentle on the stomach, liver and kidneys. They do not contain caffeine, acetaminophen, ibuprofen or other NSAIDs, have no side effects or known drug interactions and can safely complement prescription medications.*

“61% of pain sufferers declared in our own survey that they delay taking pain medication when they need it, primarily due to concerns over side effects, long-term risks or addiction2. Hyland’s pharmacists developed these new products as we believe they deserve natural pain relief that is tough on pain, yet gentle on the body. They have no known drug interactions or side effects, so you feel better, safely.” said Hyland’s President, Les Hamilton.

For over a century, Hyland’s has provided families with comfort and care through offering safe homeopathic remedies using the highest quality natural active ingredients while following the strictest standards of preparation.

Hyland’s NEW Pain Relief Line:

  • Uses natural active ingredients
  • No caffeine, acetaminophen, ibuprofen, or other NSAIDs,
  • No known drug interactions, can safely complement prescription medications
  • No side effects
  • Gentle on stomach, liver, and kidneys
  • Non-drowsy, non-habit forming
  • Quick dissolving tablets, no water needed
  • For adults and children 12+ years

Line Includes:

  • Migraine Relief, including throbbing or pounding migraine pain, dull or frontal headache, light/noise sensitivity, dizziness, nausea, and blurred vision
  • Headache Relief
  • Backache Relief
  • Pain Relief – For muscle, joint, head, neck, or back pain
  • Fever Reducer, to reduce fever and pain symptoms

With the launch earlier this year or Hyland’s 4 Kids Pain Relief for the little ones and FLEXmore™, Arthritis Pain Relief, Hyland’s now offers a natural approach to pain management for the whole family.

Hyland’s new Pain Relief Line can be purchased at select Walgreens stores nationwide and online at Hylands.com and Amazon.com.

About Hyland’s

Hyland’s, Inc., a division of Standard Homeopathic Co., develops homeopathic medicines with the highest quality natural active ingredients, following the strictest standards of preparation. With its commitment to excellence for over a century, consumers can trust all Hyland’s products to provide natural & gentle relief that is safe for the entire family. For more information, visit http://www.hylands.com

1 https://files.sld.cu/anestesiologia/files/2012/04/painfactsandstats.pdf 7

2 Hyland’s Pain Attitude & Usage Survey of over 500 pain sufferers, 2020

*Claims based on traditional homeopathic practice. Not accepted medical evidence. Not FDA evaluated.

Share article on social media or email:

Mediaplanet’s 2020 Vision Health Edition Features Night Vision Disturbances and Ocuphire Pharma’s Leadership in Investigating Potential Treatments for the Condition


News Image

“We are committed to raising the awareness of both the problem and its potential treatment, with our efforts in evaluating an eye drop drug candidate called Nyxol entering Phase 3 clinical trials”

Today, Mediaplanet announces the launch of this year’s edition of the “Vision Health” publication in print and digital formats. This campaign covers the day-to-day vision challenges that patients, seniors, caregivers, and medical professionals confront, as well as highlights the best therapies to preserve vision which so profoundly determines the quality of life for every individual.

Many people are unaware of the early symptoms of vision problems that can lead to significant ophthalmic damage or vision disturbance. These disabilities and conditions include diabetic retinopathy, thyroid eye disease, keratoconus and night vision disturbances, all of which can significantly degrade quality of life. If people fail to recognize early symptoms or simply try to manage through a period of deterioration, they risk missing opportunities to arrest disease progression or to easily treat serious impairments. This campaign will shed light on factors that patients should be aware of in order to generate earlier self-intervention to maximize their eye health and visual performance.

One pervasive condition that will be addressed with this campaign is night, or dim-light, vision disturbances. This is a condition characterized by distortions in a person’s vision in dim or dark conditions by the appearance of glare, halos or blurriness around light sources, especially while driving. The disturbances arise when natural pupil dilation exposes imperfections on the cornea surface, which then distort the path of light to the retina.

Ocuphire Pharma is an ophthalmic drug development company that has been pioneering the study of dim light disturbance in clinical trials. “The condition of night vision disturbances affects tens of millions of Americans and yet there is currently no FDA-approved drug treatment option for eye doctors to offer to patients,” said Mina Sooch, CEO and Founder of Ocuphire. “We are committed to raising the awareness of both the problem and its potential treatment, with our efforts in evaluating an eye drop drug candidate called Nyxol entering Phase 3 clinical trials.”

The print component of “Vision Health” is distributed within today’s Personal Health edition of USA TODAY in New York, Chicago, Los Angeles, San Francisco, Boston, Washington D.C./Baltimore, Philadelphia and Dallas markets, with a circulation of approximately 200,000 copies and an estimated readership of 600,000. The digital component is distributed nationally, through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/vision-and-hearing/

This campaign was made possible with the support of Ocuphire Pharma.

About Ocuphire Pharma

Ocuphire is a privately-held, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit http://www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase 2 clinical trials. For more information, please visit http://www.ocuphire.com.

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Share article on social media or email:

SweetLeaf’s New Line of Organic Monk Fruit Earns Editors’ Pick Award From Progressive Grocer


News Image

It’s gratifying to know that the prestigious trade publication, Progressive Grocer, has recognized our delicious, better-for-you Organic Monk Fruit as its Editor’s Pick. We are extremely happy and excited to be able to offer these great-tasting, new sugar-alternatives to consumers.”

The food and grocery industry publication, Progressive Grocer, has just announced its choice of SweetLeaf’s new product line, Organic Monk Fruit as a prestigious 2020 Editors’ Pick for Excellence, an extremely competitive and much sought-after award.

Discovered by Southeast Asian Monks nearly 1,000 years ago, monk fruit is a green, round, melon-looking fruit which grows on a vine and has been used for centuries in traditional Chinese medicine. The Food and Drug Administration (FDA) approved its use as a sweetener a decade ago.

Monk fruit, which is naturally 300-400 times sweeter than cane sugar, is an outstanding source of antioxidants, which boosts the immune system. With a non-glycemic response, zero calories/carbs, and zero sugars, the line of 19 products is a perfect sugar alternative.

SweetLeaf Organic Monk Fruit is available in granular bags and packets, 50ml squeezable organic liquids, and 2-oz organic monk fruit liquid drops making it easy to use as an alternative for sugar in baking, cooking, favorite drinks, recipes, and more. Delicious, very today flavors include: Caramel Macchiato, Orange Passionfruit, Almond Amaretto, French Vanilla, Old Fashion Lemonade, Strawberry Guava, English Toffee, Creme Brulee, and Chocolate Peanut Butter.

SweetLeaf’s Brand and Marketing Director, Brian Jensen said, “Today’s consumers are looking for healthier alternatives to sugary foods and sweetened beverages of all kinds, while still enjoying great taste. SweetLeaf Organic Monk Fruit’s full product line is poised to provide millions of people with a healthful solution for replacing sugar in their diets. It’s gratifying to know that the prestigious trade publication, Progressive Grocer, has recognized our delicious, better-for-you Organic Monk Fruit as its Editor’s Pick. We are extremely happy and excited to be able to offer these great-tasting, new sugar-alternatives to consumers.”

Besides its award-winning Organic Monk Fruit, SweetLeaf also manufactures SweetLeaf Stevia and SweetLeaf Organic Stevia in packets and shaker jar; Water Drops® water enhancer in six fruit blends; delicious Sweet Drops® in 2-ounce or convenient 50ml bottles, and Better Than Sugar!®, available in granular and powdered, natural and organic, a one-to-one sugar replacement.

SweetLeaf Organic Monk Fruit is available online at Shop.SweetLeaf.com and online retailers and soon in natural and conventional grocery stores.

For samples or interviews with company leadership, please contact the name listed at the bottom of the release.

About WISDOM NATURAL BRANDS®, maker of SweetLeaf Sweeteners

Wisdom Natural Brands®, based in Gilbert, Ariz., has been the leading stevia expert and industry pioneer with its plant-based SweetLeaf® Sweeteners brand for 38 years. SweetLeaf is the only stevia brand winning 37 awards for taste and innovation. SweetLeaf Organic Monk Fruit is a 1:1 sugar replacement and available in granular, squeezable, and liquid drops, totalling 18 products. SweetLeaf Sweeteners have zero calories, zero sugars, a non-glycemic response, and no artificial ingredients. SweetLeaf Stevia is sold in boxes containing 35 or 70 packets and shaker jars (organic or natural) for easy home use. SweetLeaf Liquid Stevia Sweet Drops® add flavor with zero sugars, and no calories or artificial sweeteners to foods, beverages, and recipes. Organic Sweet Drops are available in three popular flavors: English Toffee, Vanilla Crème, and SteviaClear®. SweetLeaf Stevia Water Drops® add delicious flavor to still or sparkling water. New Better than Sugar!® powdered and granular, natural and organic, is a sugar replacement measuring cup-for-cup like sugar—without any of the calories or carbs and with zero sugar. SweetLeaf Sugar-Free Stevia Syrup, in three popular flavors, brings the incredible sweetness of stevia and monk fruit, with only 70 calories per serving. Wisdom introduced herbal blends made from Yerba Maté through its Wisdom of the Ancients® brand, one of the most respected herbal lines in the natural industry. Wisdom of the Ancients herbal blends are available in bags and loose leaves and come in a variety of beneficial flavors. And new zero-sugar, zero-calorie Yerba Maté Energy Shots, available in regular and orange flavors, provide energy with 200 nutrients and 100% naturally occurring caffeine. SweetLeaf Sweeteners and Wisdom of the Ancients’ products are available at: Shop.SweetLeaf.com, health food stores, natural groceries, supermarkets, and online retailers.

MEDIA CONTACT:

Barbara McFadden    

McFadden/Gavender

M: (520) 990-6040

barbara@mcfaddengavender.com

Website:

SweetLeaf.com

WisdomNaturalBrands.com

Share article on social media or email:

Villa Healthcare Celebrates Christa Kelly as Skilled Nursing News Future Leader


News Image

Villa Healthcare Celebrates Christa Kelly as Skilled Nursing News Future Leader

“Christa is an energetic leader who has developed and trained her department to utilize data and analytics to influence how care and service can be provided, while improving the wellbeing of all served.”

Villa Healthcare celebrates Christa Kelly, Vice President of Business Development, on her win for Skilled Nursing News 2020 Future Leader. The Future Leaders Awards, presented by Aging Media Network, recognizes high-performing employees who are shaping the next decade of care delivery across the senior housing, skilled nursing, home health and hospice industries. These passionate workers know how to put vision into action for the good of seniors and aging industry professionals, and they are committed to the wellbeing of the aging population and the industries they serve.

Christa is an advocate for seniors and brings this into everything she does within the skilled nursing business. On a personal level, Christa provides support for patients who are in a highly emotional time through reassurance, following up while they are in the facility, remembering their preferences, and overall showing her genuine care for their wellbeing. For one patient, this may mean baking banana bread as it’s her favorite and for another, it’s as simple as remembering his name to say hello. On a broader level, Christa teaches this to her team and stresses the importance of easing a patient’s loneliness, anxiety, and frustrations. Christa knows it can be a challenging place for patients, from hospitalization, surgery, financial strains and more. This means doing what is best for the patients and meeting their needs so they receive the best care.

Christa is a rare leader who can put vision into action. She is able to understand the complex system of serving a patient’s needs, while juggling the needs and requirements of the hospital and payors. Working with preferred providers and their hospital systems is the new normal in healthcare and the skilled nursing facility world. Christa has developed and maintains relationships to satisfy the full system while providing cohesiveness in care.

Christa’s experience in the field further demonstrates her leadership skills and abilities. She started in 2010 as Admissions Assistant, working her way up over the past ten years. She brings value to her position in knowing the entire process and how different positions operate, which makes her uniquely able to guide, mentor, challenge, and lead her team. Christa’s perspective of having been in different positions creates a better ability to problem solve.

Regarding her operational role, Christa leads the sales strategy within Villa’s 34 skilled nursing facilities. She utilizes different strategies based on building and community needs. Christa reviews the clinical programs at each center to meet hospital focus while utilizing Medicare data to determine trends. Within Villa, Christa is known for her leadership in business development initiatives that are consistent with the company’s overall strategy, meaning both Clinical and Operational needs working together, while adhering to company vision.

Avi Lev, Chief Marketing Officer says “Christa Kelly is the textbook definition and example of a high-performing employee shaping the next decade of care delivery. She has illustrated the ability to enter new markets and identify ways to care for patients in those markets. As healthcare providers, we must migrate to market need, not the other way around. Christa has been able to identify programs and services that cater to what the market needs or is seeking. Christa has also created Physician alignment to ensure a strong continuum of care, a fundamental element in post-acute care. Her ability to partner and align all the moving pieces of the post-acute environment has been a skill that Christa has brought to Villa and the industry, ensuring a positive patient experience.”

Paxton Wiffler, Executive Vice President shares “Christa is an energetic leader who has developed and trained her department to utilize data and analytics to influence how care and service can be provided, while improving the wellbeing of all served. This positive disruptive behavior has helped transform the organization from being focused on the same “old things” to how service can be tailored within facilities, anticipating the needs of the seniors, and creating raving fans within the buildings. This culture of service is often talked about, but rarely actualized. Christa has built a team and influenced an organization dedicated to making it a reality, not in one skilled nursing facility, but in an organization spanning multiple states.”

We’re Villa, and we make people better. Of course, we’re focused on quality care and good outcomes. But we’re here to do so much more. Villa’s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We’ve always wanted to be a part of something greater, and we’re making that a reality. Our commitment to our people, our environment and clinical programs will allow us to fulfill our mission of making people better. For more information, please visit http://www.VillaHC.com.

####

Share article on social media or email:

The Gildred Companies Announces Gregg Haggart is a Finalist in the San Diego Business Journal’s 2020 CEO of the Year Awards


It is especially inspiring during the COVID-19 pandemic to hear from other leaders working through the challenges and finding success in these unusual times.

The Gildred Companies is pleased to announce that the company’s CEO, Gregg Haggart, is a finalist in the San Diego Business Journal’s CEO of the Year awards. The event recognizes significant achievements of local leaders within their companies, sector and in the community.

“I’m honored to be named among this group of CEOs who are driving business forward in San Diego” said Haggart. “It is especially inspiring during the COVID-19 pandemic to hear from other leaders working through the challenges and finding success in these unusual times. I’m proud to represent the achievements of The Gildred Companies on behalf of our entire team.”

Under Gregg Haggart’s stewardship, The Gildred Companies own and manage a portfolio of real estate in Southern California serving over 200 tenants. Recent accomplishments by the team led by Haggart include the development of a 50-megawatt solar project on a long held Gildred parcel in the Anza Borrego Desert. The project is designed to help San Diego achieve its Climate Action Plan goals and power over 20,000 homes without using carbon-based fuel and provide both clean energy and jobs in the region. The successful purchase and redevelopment of Ocean Point Tech Center in Carlsbad was led by Gregg, and most recently he is successfully navigating the COVID-19 pandemic while keeping the entire team intact.

This year the CEO of the Year awards event will be held virtually on September 30, 2020, from 2:00 – 3:30 p.m. PDT, and attendance is possible by registering on the SDBJ website. Winners will be announced in various categories, such as public company, privately held company, nonprofit, government agency and education.

See the full list of finalists here.

About The Gildred Companies

The Gildred Companies has a legacy of over 90 years of investing in San Diego and supporting its culture and economy. The company began in 1927 with the construction and operation of the landmark San Diego Fox Theater Building, now Copley Symphony Hall and Symphony Towers. Today the Gildred Companies is a diversified organization with assets throughout Southern California including a portfolio of industrial and business parks, new developments in real estate and renewable power, and strategic investments in complementary business opportunities. Learn more at http://www.GildredCo.com

Share article on social media or email: